TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Array Biopharma Inc (NASDAQ:ARRY) Investor Investigation Concerning Possible Wrongdoing Announced

  • If you purchased shares of Array Biopharma Inc (NASDAQ:ARRY), you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

Company
Array Biopharma Inc
Security
NASDAQ: ARRY

Summary

August 31, 2016 (Shareholders Foundation) - An investigation on behalf of current long-term investors in shares of Array Biopharma Inc (NASDAQ:ARRY) was announced over potential breaches of fiduciary duties by certain officers and directors at Array Biopharma Inc.

The investigation by a law firm concerns whether certain Array Biopharma directors breached their fiduciary duties and caused damage to the company and its shareholders.

Array Biopharma Inc reported that its Total Revenue rose from $51.91 million for the 12 months period that ended on June 30, 2015 to $137.88 million for the 12 months period that ended on June 30, 2016 while its Net Income of $9.37 million declined to a Net Loss of $92.84 million over those respective time periods.

Shares of Array Biopharma Inc (NASDAQ:ARRY) declined from as high as $8.24 per share in February 2015 to as low as $2.50 per share in February 2016.

On August 31, 2016, NASDAQ:ARRY shares closed at $3.43 per share.

Start Monitoring Your Investments